Dépistage de la trisomie 21 fœtale par les marqueurs sériques maternels

There is now a need to improve this screening in order to reduce amniocentesis rate. So the combination of the ultrasound (nuchal translucency) and biochemical markers (of the first trimester such as pregnancy associated plasma protein and free beta-hCG, or those of the second trimester) is the present challenge.